SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 91 000 KRW -0.11% Market Closed
Market Cap: 7.1T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+54%
Revenue
Forecast
+25%
Operating Income
Forecast
+59%
Net Income
Forecast
+3%

Wall Street
Price Targets

Price Targets Summary
SK Biopharmaceuticals Co Ltd

Wall Street analysts forecast SK Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 139 980 KRW with a low forecast of 70 700 KRW and a high forecast of 173 250 KRW.

Lowest Forecast
Wall Street Target
70 700 KRW
22% Downside
Average Forecast
Wall Street Target
139 980 KRW
54% Upside
Highest Forecast
Wall Street Target
173 250 KRW
90% Upside
Lowest
Price Target
70 700 KRW
22% Downside
Average
Price Target
139 980 KRW
54% Upside
Highest
Price Target
173 250 KRW
90% Upside
SK Biopharmaceuticals Co Ltd Competitors:
Price Targets
4151
Kyowa Kirin Co Ltd
9% Upside
MRK
Merck KGaA
50% Upside
000423
Dong-E-E-Jiao Co Ltd
49% Upside
ORMP
Oramed Pharmaceuticals Inc
53% Upside
4151
Kyowa Kirin Co Ltd
9% Upside
MRK
Merck KGaA
50% Upside
000423
Dong-E-E-Jiao Co Ltd
49% Upside
ORMP
Oramed Pharmaceuticals Inc
53% Upside
ZYDUSLIFE
Zydus Lifesciences Ltd
7% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
17% Upside
NEU
Neuren Pharmaceuticals Ltd
103% Upside
OCUL
Ocular Therapeutix Inc
115% Upside

Revenue
Forecast

Revenue Estimate
SK Biopharmaceuticals Co Ltd

For the last 6 years the compound annual growth rate for SK Biopharmaceuticals Co Ltd's revenue is 182%. The projected CAGR for the next 3 years is 25%.

182%
Past Growth
25%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
SK Biopharmaceuticals Co Ltd

The compound annual growth rate of SK Biopharmaceuticals Co Ltd's operating income for the next 3 years is 59%.

N/A
Past Growth
59%
Estimated Growth
Estimates Accuracy
13%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
SK Biopharmaceuticals Co Ltd

The compound annual growth rate of SK Biopharmaceuticals Co Ltd's net income for the next 3 years is 3%.

N/A
Past Growth
3%
Estimated Growth
Estimates Accuracy
9%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SK Biopharmaceuticals Co Ltd's stock price target?
Price Target
139 980 KRW

According to Wall Street analysts, the average 1-year price target for SK Biopharmaceuticals Co Ltd is 139 980 KRW with a low forecast of 70 700 KRW and a high forecast of 173 250 KRW.

What is SK Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
25%

For the last 6 years the compound annual growth rate for SK Biopharmaceuticals Co Ltd's revenue is 182%. The projected CAGR for the next 3 years is 25%.

What is SK Biopharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
59%

The compound annual growth rate of SK Biopharmaceuticals Co Ltd's operating income for the next 3 years is 59%.

What is SK Biopharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
3%

The compound annual growth rate of SK Biopharmaceuticals Co Ltd's net income for the next 3 years is 3%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.